Nitrocine discontinuation August 10, 2021

See attached correspondence:

ISOKET Dosage Card

Nitrocine Discontinuation Notice

In summary:

  • An online GSK and Ethicare meeting was held Wednesday 4th August  to prepare Professional bodies verbally of the discontinuation and provide an opportunity for discussion,  to avoid Specialists from receiving a letter with no forewarning. All relevant Professional bodies were invited, however attendance was limited.
  • A stock build of 18 months’ supply based  on the past years run rate has been created. The stock is on controlled supply, to avoid overbuying and depleting the stock build, providing specialists time to move over to Isoket, which is the remaining IV nitrate in the market.
  • GSK reason for discontinuation was a commercial decision due to the complexity of manufacturing the two nitrates, and the demand globally for Isoket verses Nitrocine is 70/40%. In SA Nitrocine is the favourable molecule however the SA market is small in comparison.
  • GSK will continue to  manufacture Isoket and are committed to providing stable supply of the remaining IV Nitrate in the SA market.
  • I have attached the digital dosage card for Isoket, for ease of transition for Specialists, ICU and Cath Lab sisters.
  • Any objections and queries, please contact Alison.McIlree@ethicaresa.com
Posted in

Other Articles

Standard Operating Procedure for sponsorships requests for support to Critical Care Congress or Scientific Meeting attendance

The document outlines the process to follow for applications for funding by CCSSA members for support from…

Applications Invited: Australian and New Zealand Intensive Care Society,(ANZICS) 2023 Intensive Care Global Rising Star Programme

Dear  CCSSA Members   The Australian and New Zealand Intensive Care Society(ANZICS)  has  invited applications  for the…

32nd Argentine and International Intensive Care Congress

The event is being organised by the Sociedad Argentina de Terapia Intensiva and will be held in…